- Home
- FCAP vs CLNN Comparison
FCAP vs CLNN Comparison
Compare FCAP & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | CLNN |
|---|---|---|
| Founded | 1891 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.0M | 48.4M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | FCAP | CLNN |
|---|---|---|
| Price | $49.00 | $5.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | 2.2K | ★ 54.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.43 | N/A |
| Revenue | ★ $7,059,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $82.05 |
| P/E Ratio | $13.97 | ★ N/A |
| Revenue Growth | ★ 0.71 | N/A |
| 52 Week Low | $33.88 | $2.28 |
| 52 Week High | $71.00 | $13.50 |
Technical Indicators
Market Signals| Indicator | FCAP | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 59.87 |
| Support Level | $46.64 | $3.43 |
| Resistance Level | $50.75 | $5.71 |
| Average True Range (ATR) | 1.38 | 0.43 |
| MACD | -0.39 | 0.10 |
| Stochastic Oscillator | 2.84 | 98.33 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.